Merchant Group increases stake in Rhythm Biosciences
Medical diagnostics small cap Rhythm Biosciences Limited (ASX:RHY) has today announced that its new shareholder Merchant Group has increased its equity stake in the company from 5.02% to 7.01%.
This follows the announcement earlier this week detailing the news of Merchant’s substantial investment in the company. At the time RHY CEO Dr Trevor Lockett referred to Merchant as “a supportive equity partner” with an “enviable record of combining thorough research with exceptional returns”.
As always, it should be noted that RHY is a speculative play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
The Merchant Opportunities Fund is a specialist life sciences fund recognised as a successful and long-term investor in companies close to commercialisation.
The main objective for RHY at this stage of development is to commercialise the company’s simple and effective ColoSTATTM blood test for colorectal cancer.
The small cap is currently in the process of preparing reagents for the ColoSTATTM blood test, after more than a decade of research and development by both RHY and the CSIRO.
Colorectal cancer is the second biggest cause of cancer death in the world, and as such, RHY views ColoSTATTM as a potentially very important tool in the disease’s early diagnosis and treatment.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.